Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 10;25(11):2692.
doi: 10.3390/molecules25112692.

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy

Francesco Mainini  1 , Michael R Eccles  1
Affiliations
Review

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy

Francesco Mainini et al. Molecules. .

Abstract

RNA interference (RNAi) uses small interfering RNAs (siRNAs) to mediate gene-silencing in cells and represents an emerging strategy for cancer therapy. Successful RNAi-mediated gene silencing requires overcoming multiple physiological barriers to achieve efficient delivery of siRNAs into cells in vivo, including into tumor and/or host cells in the tumor micro-environment (TME). Consequently, lipid and polymer-based nanoparticle siRNA delivery systems have been developed to surmount these physiological barriers. In this article, we review the strategies that have been developed to facilitate siRNA survival in the circulatory system, siRNA movement from the blood into tissues and the TME, targeted siRNA delivery to the tumor or specific cell types, cellular uptake, and escape from endosomal degradation. We also discuss the use of various types of lipid and polymer-based carriers for cancer therapy, including a section on anti-tumor nanovaccines enhanced by siRNAs. Finally, we review current and recent clinical trials using NPs loaded with siRNAs for cancer therapy. The siRNA cancer therapeutics field is rapidly evolving, and it is conceivable that precision cancer therapy could, in the relatively near future, benefit from the combined use of cancer therapies, for example immune checkpoint blockade together with gene-targeting siRNAs, personalized for enhancing and fine-tuning a patient's therapeutic response.

Keywords: cancer therapy; intracellular delivery; nanoparticle; siRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
RNAi-based therapeutics for gene silencing.
Figure 2
Figure 2
The intracellular barriers of siRNA-loaded NPs as nanovectors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature. 1998;391:806–811. doi: 10.1038/35888. - DOI - PubMed
    1. Ameres S.L., Martinez J., Schroeder R. Molecular Basis for Target RNA Recognition and Cleavage by Human RISC. Cell. 2007;130:101–112. doi: 10.1016/j.cell.2007.04.037. - DOI - PubMed
    1. Robb G.B., Rana T.M. RNA Helicase A Interacts with RISC in Human Cells and Functions in RISC Loading. Mol. Cell. 2007;26:523–537. doi: 10.1016/j.molcel.2007.04.016. - DOI - PubMed
    1. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–355. doi: 10.1038/nature02871. - DOI - PubMed
    1. Paddison P.J., Caudy A.A., Bernstein E., Hannon G.J., Conklin D.S. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 2002;16:948–958. doi: 10.1101/gad.981002. - DOI - PMC - PubMed